Search Results for: covid-19
Articles
BioPlx Announces Focus on Developing Cure for Antibiotic-Resistant Bacteria August 25, 2021
Antimicrobial Resistance (AMR) is one of the greatest threats to society, human and animal health, and economic prosperity. Those are...Junshi & Coherus Biosciences Announce Positive Interim Results of CHOICE-01 Phase 3 Clinical Trial August 23, 2021
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. recently announced positive interim results from the pivotal study CHOICE-01 (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating….
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients With Severe Exocrine Pancreatic Insufficiency August 23, 2021
AzurRx BioPharma recently announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard...ProPhase Labs Acquires Whole Genome Sequencing Company August 17, 2021
ProPhase Labs, Inc. recently announced the acquisition of Nebula Genomics, a privately-owned personal genomics company. The company’s recently formed subsidiary,...Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders August 10, 2021
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….
Sensirion Expands its Flow Sensor Portfolio for Ventilators August 10, 2021
Sensirion, the sensor expert for medical ventilation and the world’s leading manufacturer of flow sensors, is expanding its product portfolio...Syneos Health & Aetion Partner to Offer RWE Solutions to Advance Drug Development & Commercialization August 4, 2021
Syneos Health and Aetion recently announced a partnership to provide regulatory-grade data and analytics-driven solutions to advance drug development and improve patient outcomes….
Croda Expands its High Purity Pharmaceutical Excipients Manufacturing Capability August 4, 2021
Croda Inc. officially opened its newly expanded pharmaceutical excipients facility with a ribbon cutting celebration. The event, led by Mill...Dyadic Announces Technology Transfer & Licensing Agreement With South Africa’s Rubic Consortium July 28, 2021
Dyadic International, Inc. recently announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a...Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe July 21, 2021
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions...Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate July 8, 2021
Valneva SE recently announced it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the...BioAegis Awarded BARDA Contract to Advance Development of a Novel Host-Directed Human Protein for Patients With Sepsis & Severe Infection July 1, 2021
BioAegis Therapeutics Inc. recently announced it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, to further….
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles July 1, 2021
Halberd Corporation recently announced a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the...OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi July 1, 2021
OSE Immunotherapeutics and Cenexi recently announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics'...Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial July 1, 2021
Altimmune, Inc. recently provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The company also provided...2021 Respiratory Drug Development eBook – The Three Cs Driving Respiratory Drug Delivery June 29, 2021
In this third annual Drug Development & Delivery Respiratory eBook, several companies discuss what they are currently working on to propel the respiratory sector.
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin June 29, 2021
Veru Inc. recently announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton...Onconova Therapeutics Provides Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer June 29, 2021
Onconova Therapeutics, Inc. recently announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced...Fulcrum Therapeutics Announces Results from ReDUX4 Trial With Losmapimod in Facioscapulohumeral Muscular Dystrophy Demonstrating Slowed Disease Progression & Improved Function June 29, 2021
Fulcrum Therapeutics, Inc. recently announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy (FSHD). Results being presented with….
Onconova Therapeutics Announces Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined With Immune Checkpoint Blockade June 23, 2021
Onconova Therapeutics, Inc. recently announced the publication of a preclinical study in the journal Molecular Cancer. The study, titled Novel...
